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Abstract
Background: Endothelial dysfunction is considered as a risk factor for cardiovascular disease, which is a consistent
finding in diabetic mellitus type 2 (DMT2). First-degree relatives of DMT2 patients have a higher risk of developing
DMT2 later on the life. We aimed to investigate whether impaired endothelial function exists in siblings of DMT2
patients.
Methods: As endothelial function markers, plasma E-selectin, soluble inter-cellular adhesion molecule-1 (sICAM-1), and
endothelin-1 (ET-1) were measured on 27 DMT2 patients (9 m/18f; mean age: 48.48 ± 6.75 years), 28 siblings of DMT2
patients (14 m/14f; mean age: 44.54 ± 7.10 years), and 30 control subjects (18 m/12f; mean age: 44.72± 7.56 years)
without any family history of diabetes. All the groups were matched by gender, age, and body mass index (BMI).
Results: Plasma levels of ET-1, sICAM-1, and E-selectin were significantly higher in the DMT2 group compared to the
control group (ET-1:0.79 ± 1.63 pg/ml vs. 0.33 ± 0.08 pg/ml; PCD = 0.049, sICAM-1: 71.15 ± 27.20 ng/ml vs. 34.57 ± 22.
56 ng/ml; PCD = 0.001, E-selectin: 22.45 ± 11.57 ng/ml vs. 16.28 ± 7.50 ng/ml; PCD =0.026). There was a significant
difference in sICAM-1 levels between siblings (62.08 ± 26.37 ng/ml) and controls (PCS = 0.002), but not between siblings
and DMT2 patients (PSD = 0.411). Moreover, a significant difference was observed in ET-1 levels between siblings (0.75
± 1.26 pg/ml) and controls (PCS = 0.031), but not between siblings and DMT2 patients (PSD = 0.751). There was also a
significant difference in E-selectin levels between DMT2 patients and siblings (16.56 ± 8.71 ng/ml; PSD =0.028); however,
the difference in E-selectin levels was not statistically significant between siblings and controls (PCS = 0.919).
Conclusion: Endothelial function markers in the siblings of DMT2 patients are increased in comparision to the control
group Therefore; family history in the DMT2 patients seems to be a risk factor for endothelial function. Furthermore,
endothelial dysfunction is available very early in the DMT2 patients, even before overt hyperglycemia ensues (in siblings),
and may play a key role in the etiopathology of the vasculopathy associated with DMT2.
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Background
The endothelial cell lines the internal lumen of all the vas-
culatures and serves as an interface between circulating
blood and vascular smooth muscle cells [1]. Endothelium
serves as a physical barrier between the blood and tissues.
Morover, it is able to respond to chemical and physical
signals by production of a wide range of factors that
regulate vascular tone, cellular adhesion, smooth muscle
cell proliferation, and vessel wall inflammation [2].
Endothelial dysfunction has been reported in cardio-
vascular and metabolic disorders such as coronary heart
disease [3], diabetic mellitus type I (DMT1), and diabetic
mellitus type II (DMT2) [4]. The role of endothelial dys-
function is proved to be more complicated in DMT2
than in DMT1. Moreover, the effects of hyperlipidemia,
aging, hypertension, and other factors add to the prob-
lem complexity [5–7]. Endothelial dysfunction and
inflammation, as indicated by abnormal flow-dependent
vasodilatation, increase circulating levels of adhesion
molecules, soluble intercellular adhesion molecule-1
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(sICAM-1), and E-selectin [8] known to occur in pa-
tients with DMT2 [9, 10].
E-selectin is a cell adhesion molecule expressed only
on endothelial cells activated by cytokines. Like other
selectins, it plays an important part in inflammation
[11]. During inflammation, E-selectin plays an important
role in recruiting leukocytes to the site of injury. The
local release of cytokines IL-1 and TNF-α by damaged
cells induces the over-expression of E-selectin on endo-
thelial cells of nearby blood vessels [12].
ICAM-1 is a member of the immunoglobulin superfam-
ily. Moreover, ICAM-1 is regarded as a transmembrane
protein possessing an amino-terminus extracellular do-
main, a single transmembrane domain, and a carboxy-
terminus cytoplasmic domain [13].
On the other hand, endothelin-1 (ET-1), a potent vaso-
constrictor peptide, is potentially involved in the vaso-
motor dysregulation of patients with diabetes as well as in
the development of their vascular complications [14, 15].
Further, both hyperglycaemia and insulin administration
elevate circulating levels of ET-1 [9, 10]. As ET-1 plays a
pathophysiologic role in various forms of cardiovascular
disease, it has been suggested to be a potential factor in
endothelial dysfunction [16].
In fact, markers of endothelial function are often ele-
vated years before any sign of microangiopathy becomes
evident [5–7]. First-degree relatives (FDR) of DMT2 pa-
tients are at increased risk of coronary artery disease
and also have a lifetime risk of developing DMT2 of up
to 40 % [17]. Development of these dysfunctions appears
to be predicted by the presence of features of insulin re-
sistance and associated clustering of atherosclerotic risk
in these subjects [18]. In addition to the insulin resist-
ance found in young FDRs [19, 20], family studies have
revealed that FDRs of individuals with DMT2 are about
3 times more likely to develop DMT2 than individuals
without a positive family history of the disease [21, 22].
This research aimed to assess endothelial function in
FDRs and compare it with that in DMT2 and normal
subjects. Moreover, considering that diabetic patients
display altered endothelial function, we designed the
present study so that circulating levels of endothelial
function markers could be assessed in patients with
DMT2 and their siblings.
Methods
Subjects
The participants in this study included 27 patients with
DMT2, 28 siblings of DMT2 patients, and 30 control
subjects with an age range from 30–60 years. Non-
smoker patients who had DMT2 after the age of 30 were
only classified as having DMT2 and therefore, included
in the study. Patients were then asked to encourage their
siblings to participate in the study and the significance
of the study was clarified to those willing to participate.
Further, siblings of type 2 diabetic patients, matched for
age, gender and body mass index (BMI) were studied.
Control subjects without personal or close family his-
tory of DMT2 were then selected to be matched with
the DMT2 patients and their siblings in terms of age,
gender and BMI. This study was conducted in accord-
ance with the Declaration of Helsinki [23], and its re-
vised version was ultimately accepted by the Ethics
Committee of UMSU, Urmia, Iran. All the patients were
required to give written informed consent prior to par-
ticipating in the study.
Blood specimens
Peripheral heparinized blood samples (5 ml) were col-
lected from the subjects in the morning after an over-
night fasting in clean glass tubes and then centrifuged at
3000 rpm for 6 min. The plasma was then separated and
stored at−80 °C until analysis.
Assessment of endothelial function markers and fasting
blood sugar (FBS)
All the obtained samples were subjected to the following
investigations: 1) Determining plasma concentrations in
sICAM-1, ET-1, and sE-selectin using enzyme-linked
immunosorbent assay kits (IBL; North America), 2)
Determining plasma fasting blood sugar according to
the glucose oxidase method (ZistChemi Diagnostics;
Iran) using an autoanalyzer.
Exclusion criteria
Subjects were carefully selected to exclude conditions
that could interfere with endothelial dysfunction
markers, including coronary heart disease, smoking,
hypertension, bronchial asthma, acute or chronic inflam-
matory diseases, autoimmune diseases, and medications
like steroids and antipsychotic drugs.
Statistical analysis
Mean and P values were estimated using SPSS (version
18). Results are expressed as mean ± SD. Moreover, mul-
tiple comparison tests were performed using ANOVA,
followed by LSD and post-hoc analysis to locate any dif-
ferences. A P-value less than 0.05 indicated statistical
significance.
Results
The demographic and clinical characteristics of the ex-
perimental population are listed in Table 1. Twenty-
seven patients with DMT2 (33.3 % male), 28 siblings of
DMT2 patients (50 % male), and 30 control individuals
(60 % male) were studied. Duration of disease in the
DMT2 patients was 92.89 ± 67.97 month. The results
showed significant differences in fasting blood sugar
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levels in the DMT2 patients (187.08 ± 50.79 mg/dl) com-
pared to those in the siblings (89.25 ± 7.69 mg/dl) and
the controls (82.99 ± 6.46 mg/dl) (p < 0.0001, for both).
However, the difference in plasma glucose levels be-
tween the siblings and the control individuals was not
statistically significant (p = 0.452), as shown in Table 1.
As shown in Table 2, plasma levels of ET-1 were
significantly higher in the DMT2 group than in the
control group (0.79 ± 1.63 pg/ml vs. 0.33 ± 0.08 pg/
ml, respectively; PCD = 0.049). In addition, there were sig-
nificant differences in ET-1 levels between the siblings
(0.75 ± 1.26 pg/ml) and the controls (PCS = 0.031), but not
between the siblings and the DMT2 patients (PSD = 0.751).
Plasma sICAM-1 levels were similar in the DMT2
patients (71.15 ± 27.20 ng/ml) and the siblings (62.08 ±
26.37 ng/ml; PSD = 0.411), but lower in the controls
(34.57 ± 22.56 ng/ml; PCD = 0.001). Data analysis also re-
vealed a significant difference in sICAM-1 levels be-
tween the siblings and the control subjects (PCS = 0.002),
and between the DMT2 patients and the control sub-
jects (PCD = 0.001), as indicated in Table 2. Levels of
endothelial expression of sE-selectin were higher in the
DMT2 subjects (22.45 ± 11.57 ng/ml) than in the siblings
(16.56 ± 8.71 ng/ml) and the control (16.28 ± 7.50 ng/ml)
subjects (PSD = 0.028 and PCD = 0.026, respectively).
Furthermore, no significant differences in sE-selectin
concentrations were observed between the two groups
of siblings and controls (PCS = 0.919).
Discussion
Researchers have reported that FDRs of DMT2 patients
are more likely to show impaired endothelial function in
the resistance vessels than those with no family history
of the condition [24]. Ostergård et al. showed that
healthy, but insulin-resistant FDRs of DMT2 subjects
predisposed for DMT2 show minor signs of endothelial
dysfunction [25]. More recently, Caballero et al. [26]
demonstrated early abnormalities in vascular reactivity
and biochemical markers of endothelial cell activation in
individuals at risk of developing DMT2. Cellular adhe-
sion molecules are poorly expressed by the resting endo-
thelium, but are up-regulated during inflammatory
atherogenesis and may be an index of endothelial activa-
tion or even a molecular of early atherosclerosis [27].
The results indicated that the concentrations of ET-1
and sICAM-1 were significantly higher in the FDRs of
DMT2 subjects than in the control subjects. In patients
with DMT2, endothelial cell dysfunction is detectable
very early in the course of the disease, even before overt
hyperglycemia ensues, and may play a key function in
the etiopathology of the vasculopathy reported with
DMT2. The expression of VCAM-1, sICAM-1, and sE-
selectin plays a role in the initiation of the inflammatory
process [28]. However, only a few studies have examined
the development and progression of endothelial dysfunc-
tion in siblings of DMT2 patients. We found a highly
significant plasma level of ET-1 and sICAM-1 in the sib-
lings of DMT2 subjects. It is also possible that some
genetic abnormalities leading to endothelial dysfunction
could be present in individuals with family history of
DMT2, although another study found that only those
FDRs with demonstrable insulin resistance had endothelial
dysfunction [29]. We have demonstrated that FDRs of
DMT2 patients involve factor (s) capable of inducing the
expression of ET-1 and sICAM-1 in endothelial cells. This
effect cannot be directly attributed to hyperglycemia.
Table 1 Clinical and laboratory characteristics of study participants
Variable Control Siblings DMT2 PCS PCD PSD
Age (year) 44.72 ± 7.56 44.54 ± 7.10 48.48 ± 6.75 0.99 0.17 0.11
Sex (M/F) 18/12 14/14 9/18 0.44 0.10 0.21
BMI (kg/m2) 28.81 ± 4.51 30.64 ± 5.87 28.65 ± 3.84 0.17 0.96 0.13
Systolic blood pressure (mm Hg) 131.4 ± 07.6 140.8 ± 15.1 145.1 ± 11.7 0.006 <0.001 0.19
Diastolic blood pressure (mm Hg) 88.1 ± 09.9 117.6 ± 147.7 93.7 ± 11.9 0.22 0.81 0.31
Disease period (month) 0 0 92.89 ± 67.97 - - -
Fasting blood sugar (mg/dl) 82.99 ± 6.46 89.25 ± 7.69 187.08 ± 50.79 0.452 <0.001 <0.001
DMT2 diabetes mellitus type 2, PCS P value between controls and sibling, PCD P value between controls and DMT2, PSD P value between DMT2 and sibling
Table 2 Levels of endothelial function variables in DMT2, Sibling and controls
Variable Control Siblings DMT2 PCS PCD PSD
ET-1 (pg/ml) 0.33 ± 0.08 0.75 ± 1.26 0.79 ± 1.63 0.031 0.049 0.751
sICAM-1 (ng/ml) 34.57 ± 22.56 62.08 ± 26.37 71.15 ± 27.2 0.002 0.001 0.411
sE-selectin (ng/ml) 16.28 ± 7.50 16.56 ± 8.71 22.45 ± 11.57 0.919 0.026 0.028
DMT2 diabetes mellitus type 2, PCS P value between controls and siblings, PCD P value between controls and DMT2, PSD P value between DMT2 and siblings
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Increased expression of ET-1 and sICAM-1 may have a
role in the development of endothelial dysfunction in the
siblings of DMT2 subjects. The present study also shows
that Et-1 and sICAM-1 are sensitive markers of endothe-
lial activation, in contrast to sE-selectin. In a study by Dai
Wu et al. [30], the levels of E-selectin, vascular cell adhe-
sion molecule-1 (VCAM-1), total cholesterol, and trigly-
ceride were significantly elevated in FDR group compared
with controls. There were endothelial dysfunction, activa-
tion of adhesion molecule, and insulin resistance in FDRs,
and endothelial dysfunction is positively related to insulin
resistance. Similarly, Gómez et al. designed another study
in order to demonstrate whether FDRs of DMT2 subjects
present markers as a form of precocious indicators of dia-
betes mellitus. They showed ICAM-1 and VCAM-1 to be
significantly higher in the diabetic group, but not in the
family group [31]. Our study should be interpreted within
the context of its possible limitations such as low number
of subjects in the groups.
Conclusions
We showed that the subjects with DMT2 have higher ET-
1 and sICAM-1 levels than the controls. Moreover, signifi-
cant increase of ET-1 and sICAM-1 in the siblings showed
the high ability of these markers in evaluating endothelial
function. In addition, sICAM-1 and sE-selectin levels cor-
related with blood glucose. This finding confirms the im-
portance of glycaemic milieu in determining circulating
levels of endothelial function markers.
Abbreviations
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